Iproclozide

Iproclozide

SCHEMBL49744

CC(C)NNC(=O)COc1ccc(Cl)cc1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
ALDH1A1 P00352 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ATF4 P18848 4/20 0.55
NPSR1 Q6W5P4 1/20 0.54
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
SENP2 Q9HC62 1/20 0.52
SENP1 Q9P0U3 1/20 0.52
TSHR P16473 1/20 0.52
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iproclozide SCHEMBL28086223 0.86 MAOA (0.62) KMT2AMEN1NPSR1KDM4ELMNA
SCHEMBL8248742 0.85 SMN1; SMN2 (0.64) KMT2AMEN1ALDH1A1L3MBTL1ATF4
SCHEMBL12703550 0.84 LMNA (0.55) KMT2AMEN1ALDH1A1L3MBTL1RAB9A
SCHEMBL29138719 0.81 KMT2A (0.60) KMT2AMEN1ALDH1A1L3MBTL1ATF4
SCHEMBL1255820 0.81 ATF4 (0.63) KMT2AMEN1ALDH1A1L3MBTL1ATF4
SCHEMBL7492782 0.80 KMT2A (0.62) KMT2AMEN1ALDH1A1L3MBTL1ATF4
SCHEMBL9524334 0.80 ATF4 (0.61) KMT2AMEN1ALDH1A1L3MBTL1ATF4
SCHEMBL12693872 0.80 KMT2A (0.61) KMT2AMEN1ALDH1A1L3MBTL1ATF4
SCHEMBL10873062 0.78 ALDH1A1 (0.74) KMT2AMEN1ALDH1A1L3MBTL1ATF4
Hydrochloric Acid SCHEMBL27734857 0.78 KMT2A (0.60) KMT2AMEN1ALDH1A1L3MBTL1ATF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3075 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001942-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H LUNDBECK AS (DK) 2026-01-01 US claimed
WO-2025262247-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H. LUNDBECK A/S (DK) 2025-12-26 WO claimed
US-20250339403-A1 Tryptamine Formulations and Uses Thereof Natural MedTech Pty Ltd (AU) 2025-11-06 US claimed
EP-4618981-A1 COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE Remedi, Inc. (US) 2025-09-24 EP claimed
EP-4615444-A1 TRYPTAMINE FORMULATIONS AND USES THEREOF Natural Medtech Pty Ltd (AU) 2025-09-17 EP claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
EP-4479032-A1 NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS Sage Therapeutics, Inc. (US) 2024-12-25 EP claimed
US-12121513-B2 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject Intrabio Ltd. (GB) 2024-10-22 US claimed
WO-2024108195-A1 COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE REMEDI, INC. (US) 2024-05-23 WO claimed
WO-2005084654-A2 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS PHARMACIA CORPORATION (US) 2005-09-15 WO claimed
WO-2005053703-A1 COMBINATION THERAPY FOR DEMENTIA, DEPRESSION AND APATHY SHELDON LESLIE JAMES (CA) 2005-06-16 WO claimed
WO-2004041207-A2 GHB TREATMENT METHODS BAYLOR RESEARCH INSTITUTE (US) 2004-05-21 WO claimed
EP-1389115-A2 AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION Vivus, Inc. (US) 2004-02-18 EP claimed
US-20020161016-A1 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation VIVUS LLC (F/K/A VIVUS, INC.) 2002-10-31 US claimed
WO-2002041883-A2 AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION VIVUS, INC. (US) 2002-05-30 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0835660-A1 Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions Merckx, Gaston Edmond Filomena (BE) 1998-04-15 EP claimed